Drug Profile
Research programme: thrombosis and coagulation disorder therapies - Thrombotargets
Alternative Names: TT-105; TT-111; TT-112; TT-113; TT-114; TT-115; TT-116; TT-120; TT-123; TT-C01Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Thrombotargets Corporation
- Class Monoclonal antibodies; Peptides; Recombinant proteins; Small molecules
- Mechanism of Action Antifibrinolytic agents; Fibrinolytic agents; Platelet aggregation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Blood coagulation disorders; Thrombosis
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for research development in Coagulation-disorders in European Union (Parenteral)
- 04 Nov 2017 No recent reports of development identified for research development in Coagulation-disorders in European Union (Topical)
- 04 Nov 2017 No recent reports of development identified for research development in Coagulation-disorders in USA (Parenteral)